SAN DIEGO, Feb. 19, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, today announced that results from a clinical trial combining TRC105 with Inlyta® (axitinib) in patients with renal cell carcinoma will be presented at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium being held from February 26-28, 2015, in Orlando, Florida.
The presentation details are as follows:
|Abstract Title:||A Phase Ib Dose-Escalation Study of TRC105 (anti-Endoglin Antibody) in Combination with Axitinib in Patients with Metastatic Renal Cell Carcinoma (mRCC)|
|Presenter:||Toni Choueiri, M.D., Dana-Farber Cancer Institute|
|Session:||General Poster Session C (Poster Board C8)|
|Date:||Saturday, February 28, 2015|
|Times:||7:00-7:55am and 11:30-1:00pm EST (Rosen Shingle Creek Hotel)|
The poster will be available on TRACON's website (www.traconpharma.com) under the Publications section on February 28, 2015.
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC105 is also being developed in combination with VEGF inhibitor treatments in age-related macular degeneration. For more information about the clinical trials, please visit TRACON's website at http://www.traconpharma.com/clinical_trials.php.
TRACON develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
CONTACT: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 email@example.com
Source:TRACON Pharmaceuticals, Inc.